Smart4Fabry is the acronym of a H2020 funded Project that stands for “Smart functional GLA-nanoformulation for Fabry disease”. Smart4Fabry is a collaborative project funded under the H2020 EU Research and Innovation programme. This project is coordinated by Dr. Nora Ventosa, from the Institut de Ciència de Materials de Barcelona (ICMAB-CSIC) and Dra. Miriam Royo from Multivalent System for Nanomedicine group (MS4N), of the Institute for Advanced Chemistry of Catalonia (IQAC-CSIC). Both groups are part of the Spanish National Research Council (CSIC) and Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN).

Smart-4-Fabry has been conceived and created to obtain a new nanoformulation of GLA, that will improve the efficacy and toleration compared to the actual treatment with non-formulated GLA. The final benefit will be seen as considerable reduction on the Fabry disease treatment cost and a substantial improvement in the life-quality of Fabry disease patients.

Smart-4-Fabry will impact on a major health problem, the existence of new therapies for rare diseases, which constitutes a priority societal challenge as shown in the H2020 Work Programmes. Rare diseases, like Fabry disease, mean a major health problem for a significant number of people in total, but affecting small number of patients for each individual disease.

This workshop will take place on 3rd February at 14:00h.

Join the Smart4Fabry Final Workshop to learn from expert speakers how, why and for what the solution proposed by Smart4Fabry was conceived, a sign of cooperation at European level to boost nanomedicine development and translation to clinical stages.

See you there!

Download programm

Registration form


Fuente: Institute for Advanced Chemistry of Catalonia (IQAC-CSIC)

https://www.iqac.csic.es/smart4fabry-final-workshop-3rd-february/
Subscribirse al Directorio
Escribir un Artículo

Últimas Noticias

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

La Unidad de Chequeos de la Clínica sup...

El estudio realizado sobre una muestra significati...

Destacadas

Entrevista con Dámaso Molero, director ...

by 3P Biopharmaceuticals

Dámaso Molero:" Creo que en Latinoamérica habrá negocio en el d...

Cemiplimab es el primer tratamiento con ...

by Vall d’Hebron

Cemiplimab, comercializado con el nombre Libtayo® gracias a una alian...

Diapositiva de Fotos